Is Gaudium IVF the Hottest IPO of 2026? Dates, GMP, Price Band

Introduction to Gaudium IVF IPO

Founded in 2009 by Dr. Manika Khanna, Gaudium IVF has grown into a well-recognized name in the field of fertility care in India. Over the years, the company has built a reputation for combining advanced reproductive technology with personalized patient care, which has helped it earn trust among couples seeking fertility solutions.

Unlike many specialized clinics that focus only on IVF procedures, Gaudium IVF follows a holistic women’s healthcare approach. In addition to fertility treatments, it offers a wide range of services such as maternity care, gynecological consultations, reproductive diagnostics, and pregnancy support programs. This diversified service portfolio not only strengthens patient relationships but also helps the company generate multiple revenue streams.

The upcoming IPO marks a historic milestone for the healthcare sector. Gaudium IVF is set to become the first fertility services company to be listed on Indian stock exchanges, including the BSE and NSE. This listing is significant because it opens the door for public investors to participate in India’s rapidly growing fertility services industry — a space driven by rising awareness, lifestyle changes, and increasing acceptance of assisted reproductive technologies.

Overall, the company’s journey from a single clinic to a recognized fertility brand highlights its strong domain expertise, expanding service ecosystem, and long-term growth ambitions.

Gaudium IVF IPO Details

Here are the key numbers and dates you need to know:

Particulars	Details
IPO Opening Date	February 20, 2026
IPO Closing Date	February 24, 2026
Listing Date	February 27, 2026
Face Value	₹1 per equity share
Price Band	₹75 to ₹79 per share
Lot Size	189 Shares (Minimum)
Total Issue Size	₹165 Crore
Listing Exchange	NSE, BSE

Issue Structure and Objectives

The Gaudium IVF IPO consists of two components — a Fresh Issue and an Offer for Sale (OFS). Understanding the difference between these two is important because they serve different purposes and signal different things to investors.

Fresh Issue – ₹90 Crore

The Fresh Issue represents new capital that will be infused directly into the company. This money will strengthen Gaudium IVF’s financial position and support its future growth plans. Since these funds go into the business itself, investors generally view a larger fresh issue as a positive sign because it indicates the company is raising money to expand rather than just allowing shareholders to exit.

Offer for Sale – ₹75 Crore

The Offer for Sale (OFS) portion involves existing promoters and shareholders selling part of their stake to the public. The proceeds from this portion do not go to the company; instead, they go to the selling shareholders. Such sales are common in IPOs and often allow early investors to partially monetize their holdings while still retaining ownership.

How the Company Plans to Use the Fresh Issue Funds

Gaudium IVF has outlined a clear plan for deploying the ₹90 crore it expects to raise from the fresh issue:

Expansion (₹50 crore): The company intends to establish 19 new IVF centers across India, which could significantly increase its geographic reach and patient capacity. Expansion into new cities can help tap unmet demand for fertility services.
Debt Repayment (₹20 crore): A portion of the funds will be used to reduce existing borrowings. Lower debt means reduced interest costs and improved financial stability, which can strengthen the company’s balance sheet.
General Corporate Purposes: The remaining amount will be allocated toward day-to-day operations, marketing, brand building, and business development. These activities are essential for sustaining growth and improving brand visibility in a competitive healthcare segment.

Financials: How Is the Company Doing?

Gaudium IVF has delivered strong financial growth in recent years, indicating rising demand for fertility treatments and effective business execution. The company’s numbers reflect not only expansion but also improving operational efficiency — both important signs for investors evaluating a healthcare IPO.

Revenue Growth
The company’s revenue increased sharply from ₹47.9 crore in FY24 to ₹70.7 crore in FY25, representing nearly 48% year-on-year growth. Such rapid expansion suggests that Gaudium IVF is successfully attracting more patients, expanding services, and strengthening its presence in the fertility care segment.

Profitability (PAT)
Profit After Tax (PAT) has also improved significantly. Net profit rose from ₹10.3 crore in FY24 to ₹19.1 crore in FY25, almost doubling within a year. This indicates that the company is not just growing revenues but also managing costs efficiently and scaling profitably — a key factor for long-term sustainability.

Current Year Momentum
The strong performance trend appears to be continuing. In just the first half of the current financial year (up to September 2025), the company has already reported a profit of ₹12.5 crore. If this pace continues, full-year profits could surpass previous records, signaling ongoing business momentum.

Why Investors Are Excited About Gaudium IVF

Investors are closely watching Gaudium IVF because it combines strong industry tailwinds with a scalable business model and early-mover positioning. Several factors explain the growing interest:

1. First-Mover Advantage

Gaudium IVF is set to become the first fertility services company to list on Indian stock exchanges, which gives it a unique positioning. Being an early entrant in the public markets can attract investors who want exposure to the rapidly expanding fertility treatment industry before more competitors list.

2. Scalable “Hub-and-Spoke” Model

The company operates on a hub-and-spoke model, where advanced treatment facilities (hubs) support smaller satellite centers (spokes). This structure allows Gaudium IVF to serve patients in both major cities and smaller towns efficiently, keeping costs controlled while expanding reach.

3. Strong Industry Growth Potential

Demand for fertility treatments in India is expected to rise steadily over the coming years due to lifestyle changes, delayed marriages, rising infertility awareness, and improving acceptance of assisted reproductive technologies. This long-term trend creates a favorable environment for specialized fertility providers.

4. Reputation and Clinical Credibility

The company has built a reputation for handling complex fertility cases, which strengthens patient trust and enhances its brand value. In healthcare, credibility and success rates play a major role in attracting new patients, making this a meaningful competitive advantage.

Gaudium IVF IPO GMP (Grey Market Premium)

The Grey Market Premium (GMP) refers to the extra price that some investors are willing to pay for IPO shares before they are officially listed on the stock exchange. Since the grey market operates informally and outside regulatory oversight, GMP is often used as a sentiment indicator rather than a guaranteed predictor of listing performance.

As of today, the GMP for Gaudium IVF IPO is hovering around ₹13 to ₹15. Based on this range, the market is indicating a possible listing gain of roughly 16% to 18% over the issue price. This suggests that short-term traders are showing moderate optimism about the IPO’s debut.

However, it’s important to remember that GMP is not official data and can change quickly depending on:

subscription demand
overall market conditions
institutional interest
last-minute sentiment shifts

Simple takeaway:
A positive GMP signals favorable short-term sentiment, but smart investors should always combine GMP signals with fundamentals, valuation, and long-term growth potential before making a decision.

Risks Involved

While Gaudium IVF shows promising growth potential, investors should remember that IPO investing always carries risk, especially in specialized healthcare businesses. Here are some key factors to consider:

1. High Competition

The fertility treatment industry in India is becoming increasingly competitive. The market includes numerous standalone fertility clinics as well as large hospital chains that are expanding into reproductive care. This competitive pressure can affect pricing power, patient acquisition costs, and market share growth.

2. Regulatory Uncertainty

Healthcare is one of the most strictly regulated sectors, and fertility services are subject to medical, ethical, and legal oversight. Any changes in government policies, licensing requirements, or treatment regulations could impact operational flexibility, expansion plans, or profitability.

3. Employee Attrition Risk

The company has experienced relatively high turnover among medical professionals in the past. This is an important concern because fertility treatment success depends heavily on skilled specialists such as doctors, embryologists, and lab technicians. Losing experienced staff could affect service quality, patient trust, and overall performance if not managed well.

Final Thoughts

Gaudium IVF appears to be a growing company in a highly specialized and steadily expanding healthcare segment. Its recent financial performance shows strong momentum, and the company has outlined clear plans for expansion, which signals management’s confidence in future demand. Although the IPO size is relatively small at ₹165 crore, its first-mover status as a listed fertility services company makes it a noteworthy opportunity that many investors will want to track closely.

From an investment perspective, the IPO may appeal most to long-term investors who want exposure to India’s evolving healthcare and fertility services market. The business operates in a niche segment with rising demand, which could support growth over time. However, like any IPO, it comes with risks — including competition, regulatory factors, and execution challenges — so it may suit investors who are comfortable with moderate risk and a longer holding horizon.

Bottom line:
If you’re seeking a long-term healthcare play and believe in the growth potential of fertility services, this IPO could be worth considering. But as always, it’s wise to review your financial goals and consult a qualified financial advisor before applying.

Note: This article is for educational purpose only, it provides no recommendation of any sort. I am no expert to give you any recommendation so decide accordingly.